Metabolism of the peptide boronic acid proteasome inhibitor bortezomib (VELCADE™) in multiple species

被引：0
|
作者：
LaButti, J [1 ]
Pekol, T [1 ]
Wang, RH [1 ]
Hsieh, F [1 ]
Daniels, JS [1 ]
Nix, D [1 ]
Gan, LS [1 ]
Miwa, G [1 ]
机构：
[1] Millennium Pharmaceut Inc, Drug Metab & Pharmacokinet, Drug Safety & Disposit, Cambridge, MA 02139 USA
来源：
DRUG METABOLISM REVIEWS | 2003年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
82
引用
收藏
页码：41 / 41
页数：1
相关论文
共 50 条
  • [31] Development of the proteasome inhibitor Velcade™ (Bortezomib) by Julian!Adams, Ph.D., and Michael!Kauffman, MD, Ph.D.
    Bold, R
    [J]. CANCER INVESTIGATION, 2004, 22 (02) : 328 - 329
  • [32] The combination of the mTOR inhibitor rapamycin and proteasome inhibitor bortezomib is synergistic in vitro in multiple myeloma.
    O'Sullivan, Garrett
    Leleu, Xavier
    Jia, Xiaoying
    Hatjiharisi, Evdoxia
    Ngo, Hai
    Moreau, Anne-Sophie
    Tai, Yu-Tsu
    McMillin, Douglas
    Mitsiades, Constantine
    Raje, Noopur
    Hideshima, Teru
    Schlossman, Robert
    Richardson, Paul
    Munshi, Nikhil
    Anderson, Kenneth
    Ghobrial, Irene
    [J]. BLOOD, 2006, 108 (11) : 996A - 997A
  • [33] Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple- negative breast cancer
    Lei, Meng
    Feng, Huayun
    Bai, Enhe
    Zhou, Hui
    Wang, Jia
    Qin, Yanru
    Zhang, Haoyang
    Wang, Xueyuan
    Liu, Zhaogang
    Hai, Ou
    Liu, Jia
    Zhu, Yongqiang
    [J]. ORGANIC & BIOMOLECULAR CHEMISTRY, 2019, 17 (03) : 683 - 691
  • [34] Phase II trials of bortezomib (PS-341, Velcade™), a selective proteasome inhibitor, in non-Hodgkin's lymphoma
    不详
    [J]. CLINICAL LYMPHOMA, 2003, 4 (02): : 79 - 82
  • [35] A phase 8 and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib ,velcade), in patients with advanced cancer
    Dy, GK
    Thomas, JP
    Wilding, G
    Bruzek, L
    Mandrekar, S
    Erlichman, C
    Alberti, D
    Binger, K
    Pitot, HC
    Alberts, SR
    Hanson, LJ
    Marnocha, R
    Tutsch, K
    Kaufmann, SH
    Adjei, AA
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (09) : 3410 - 3416
  • [36] The proteasome inhibitor bortezomib overcomes the inhibition of osteoblast function observed in multiple myeloma
    Lund, T.
    Soe, K.
    Abilgaard, N.
    Garnero, P.
    Pedersen, P. T.
    Ormstrup, T. E. J.
    Delaisse, J.
    Plesner, T.
    [J]. BONE, 2010, 47 : S304 - S305
  • [37] Biomimetic platelet nanoparticles encapsulated with proteasome inhibitor bortezomib for multiple myeloma treatment
    Gao, Guangtao
    Xu, Yong
    Gan, Jingjing
    Cao, Xinya
    Dong, Xiaoqing
    Fang, Mengkun
    Du, Ying
    Xu, Peipei
    Che, Junyi
    Chen, Bing
    [J]. APL MATERIALS, 2023, 11 (12)
  • [38] Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells
    Ju, Donghong
    Xie, Youming
    [J]. MOLECULAR MEDICINE REPORTS, 2014, 10 (05) : 2609 - 2612
  • [39] Phase II study of proteasome inhibitor bortezomib (Velcade®) in patients with relapsed/Refractory T-cell lymphoma:: Preliminary results.
    Zinzani, Pier Luigi
    Tani, Monica
    Musuraca, Gerardo
    Stefoni, Vittorio
    Marchi, Enrica
    Fina, Mariapaola
    Baccarani, Michele
    [J]. BLOOD, 2006, 108 (11) : 697A - 697A
  • [40] Dipeptide boronic acid, a novel proteasome inhibitor, prevents islet-allograft rejection
    Wu, YL
    Han, B
    Luo, HY
    Shi, GX
    Wu, JP
    [J]. TRANSPLANTATION, 2004, 78 (03) : 360 - 366
12345